Advancing life expectancy is being paralleled by a continuous increase of elderly patients with several acute cardiovascular conditions, including acute coronary syndrome (ACS). Paradoxically, despite the rising prevalence of elderly patients, older age has been a typical exclusion criterion of randomised controlled trials assessing the efficacy and safety of therapies in these patients. Therefore, the evidence to inform optimal care delivery to elderly patients with ACS is limited.
Advancing life expectancy is being paralleled by a continuous increase of elderly patients with several acute cardiovascular conditions, including acute coronary syndrome (ACS). Paradoxically, despite the rising prevalence of elderly patients, older age has been a typical exclusion criterion of randomised controlled trials assessing the efficacy and safety of therapies in these patients. Therefore, the evidence to inform optimal care delivery to elderly patients with ACS is limited.
Challenges in the clinical management of older patients with ACS include accurate clinical assessment, optimal selection of revascularisation and antithrombotic strategies, and decisions on the appropriate level of care once the expected patient prognosis and quality of life has been determined.
In this review we provide an overview of these challenges, including practical suggestions for their management. Unless otherwise specified, by 'elderly' we mean individuals 75 years of age or older.
Clinical assessment of elderly patients with suspected ACS
A focused, accurate and rapid clinical assessment of patients with symptoms suggestive of ACS is key in elderly patients who are at higher risk of major cardiovascular adverse events as compared to younger individuals.
This assessment starts with a careful history taking and focused physical examination as well as rapid ECG interpretation. The first step in the clinical evaluation is the assessment of vital signs and of clinical and haemodynamic stability. 1, 2 Patients in critical or unstable condition (e.g. shock, refractory cardiac arrest) need emergent management and/or resuscitation.
The single most important history-related factor that helps identify myocardial ischaemia is the nature of anginal symptoms followed by a history of coronary artery disease (CAD) and the number of traditional risk factors for atherosclerosis. 3 Although atypical presentations of ACS, such as shortness of breath, fatigue, confusion or syncope are quite common in older patients, the most frequent presenting symptom in this population is still typical chest pain. 4 In general, this evaluation also includes an estimation of the pre-test probability of the presence of CAD. As age is a key determinant of the likelihood of significant CAD (Figure 1 ), this probability is usually high in older individuals but still quite variable, ranging from 24% in women aged 70-79 years with non-anginal chest pain to 93% in octogenarian men with typical chest pain. 5 Any patient complaining of chest pain (thus including older individuals) should have an ECG performed and interpreted within 10 minutes of the initial evaluation in order to define the early management ( Figure 2 ). The presence of ST-segment elevation diagnostic for acute myocardial infarction 1 (i.e. a STEMI) should trigger the activation of immediate coronary angiography for reperfusion. However, it is important to highlight that the prevalence of ECG patterns precluding the interpretation of repolarisation, such as left bundle branch block (LBBB) or artificially paced rhythm, is higher in older individuals and might lead to a underdiagnosis of acute coronary atherothrombosis. In this setting criteria to provide patients with LBBB with a diagnosis of acute myocardial infarction are useful. 6, 7 Elderly patients with chest pain consistent with STEMI without a clear ECG pattern (because of a major intraventricular conduction defect or artificial pacing) should receive urgent coronary angiography (similar to younger patients) according to the recommendation of recent European Society of Cardiology (ESC) STEMI guidelines. 1 The epidemiological fact that most non ST-segment elevation acute coronary syndromes (NSTEACSs) present in elderly patients and, vice versa, that most ACS in elderly patients are NSTEACSs is relevant for diagnostic purposes. It is important, however, to avoid the frequent confusion of labelling NSTEACS in patients with chest pain and new or presumably LBBB or other baseline ECG abnormalities ( Figure 3 ). The presence of new or presumably new LBBB is high in the elderly and present in approximately one every 20 patients with suspected ACS, 6 but only a minority of these patients eventually had an acute myocardial infarction. 7 In patients presenting with LBBB some ECG features -especially concordant ST changes -are helpful for identifying patients with true acute coronary occlusion. Also, when chest pain quickly resolves spontaneously or with nitrate treatment only, coronary angiography may be deferred after the first troponin assessment (Figure 3 ), but it is important to state that pain relief with morphine is not a sign of ischaemia resolution and should not lead to more conservative management. In the case of LBBB with persistent chest pain, especially in the case of haemodynamic or electrical instability, urgent coronary angiography should be considered (Figure 3) .
The role of biomarkers of myocardial necrosis (high-sensitivity cardiac troponin when available) might also be more challenging in the elderly. This is not because troponin is less accurate for diagnosing myocardial necrosis or the kinetics of troponin release is different, but because the proportion of patients with baseline troponin elevation is higher in the elderly, due to the coexistence of several potential causes of troponin elevation, including advanced renal dysfunction or chronic heart failure alternatively to acute myocardial ischaemia. This may complicate the diagnosis, particularly when clinical presentation is not typical. In this setting it is important to use serial determination to distinguish between chronic (delta between measurements <20%) and acute elevation. The magnitude of the elevation is also relevant. A troponin value over five times the upper range limit in patients with suspected ACS makes an alternative diagnosis unlikely. 2 Finally, elderly patients with symptoms suggestive of acute myocardial ischaemia might have several other acute syndromes, such as acute aortic syndromes, pulmonary embolism or acutely decompensated aortic stenosis, which are potentially lethal and more prevalent than in younger individuals. These conditions, different from an ACS, should be routinely considered as potential diagnoses and properly managed if confirmed. Therefore, to improve the outcome of older patients with suspected ACS, a pre-hospital evaluation of symptoms is encouraged 9 as well as the creation of chest pain units 10 that may be extremely helpful to standardise the diagnostic and therapeutic management of these challenging clinical syndromes.
Considerations for an invasive management in elderly patients
Mortality from ACS has fallen dramatically during the past 20 years due to the development of modern treatment strategies including aggressive risk factor reduction, optimised medical therapy and early coronary revascularisation. An invasive treatment strategy has proved to be superior to a conservative medical strategy not only for STEMI but also for NSTEACS, a typical disease of the elderly. Nevertheless, most of the randomised evidence proving the superiority of an invasive strategy has been performed in patients less than 75 years of age. Both European and American guidelines clearly recommend an invasive strategy irrespective of age, but probably due to the fear of more adverse effects in the elderly these patients are less likely to receive invasive treatment for NSTEACS.
The main advantage of an invasive strategy in NSTEACS patients is reduced morbidity with fewer reinfarctions and fewer readmissions during follow-up. This effect may be potentially more evident in the elderly. A meta-analysis of patient pooled datasets from the three original main trials regarding routine invasive strategy in NSTEACS (the FRISC II, the ICTUS and the RITA-3 trials) has indicated that the long-term benefit of routine invasive strategy over selective invasive strategy is attenuated in younger patients aged less than 65 years. 11 Furthermore, one meta-analysis of nine randomised trials that included age as a covariate found that early routine revascularisation in patients with non-STsegment elevation myocardial infarction reduced the risk of rehospitalisation as well as the composite endpoint of recurrent myocardial infarction or death to a greater extent in elderly compared with younger individuals. 12 Two randomised clinical trials regarding invasive treatment in NSTEACS have specifically targeted elderly patients. The Italian Elderly ACS Study randomly assigned 313 patients aged over 75 years (mean 82 years) with NSTEACS within 48 hours from symptom onset to either an early invasive strategy or an initially conservative strategy. 13 The primary endpoint, a composite of death, myocardial infarction, disabling stroke, repeat hospitalisation for cardiovascular causes or severe bleeding within one year, did not differ between the groups, but subgroup analysis revealed that the primary endpoint was significantly reduced in patients with elevated troponin on admission who were assigned to the early invasive strategy. There was no difference in the occurrence of major bleeding between the two groups. The second trial is the randomised control multicentre After Eighty Study, 14 which enrolled patients with NSTEACS aged 80 years or older and randomly assigned them to an invasive strategy (coronary angiography and any kind of coronary revascularisation plus optimal medical treatment) or to a conservative strategy (optimal medical treatment alone). In that study the primary outcome -a composite of myocardial infarction, the need for urgent revascularisation, stroke, or death -was significantly reduced in patients randomly assigned to an invasive strategy (hazard ratio 0.53, 95% confidence interval 0.41-0.69; P=0.0001) with no difference in bleeding complications. Notably, the efficacy of the invasive strategy appeared diluted with increasing age, with no effect or perhaps even harm after the age of 90 years.
An important methodological issue with both these trials is their external validity, i.e. whether they are representative of the general elderly NSTEACS population. Patients in both trials may have been highly selected. While this is not completely clear from the published papers, in the Italian Elderly ACS Study there is no screening log of all potential NSTEACS patients -only those who have signed an informed consent (n=645) are reported. About half of these were excluded for multiple reasons and only 333 (51%) were randomly assigned. In the Norwegian After Eighty Study 4187 patients with NSTEACS were screened, 2214 met one or more exclusion criteria, and only 457 were randomly assigned (11%), with over 1000 patients not included for logistic reasons. Both studies may thus have included a healthier elderly population. This must be kept in mind when evaluating the risk of side effects such as bleedings and other procedural complications, including acute kidney injury. Observational data have indeed previously documented that the risk of acute kidney injury and bleeding after invasive treatment increases with age.
In conclusion, evidence from randomised controlled trials generally supports an early invasive strategy in elderly patients with NSTEACS, with the possible exclusion of the very elderly (i.e. >90 years old). Therefore in most elderly NSTEACS patients an early invasive strategy with coronary angiography and revascularisation, if appropriate, should be considered, especially in the case of normal renal function and good functional capacity. In patients who are very old (90 years or older), with multiple severe comorbidities and/or poor functional status, a routine early invasive strategy should be balanced against the high risk of periprocedural complications, and also patient preference should be taken into account for the final decision.
Antithrombotic and bleeding minimisation strategies in the elderly with ACS
Elderly patients with ACS have a higher risk for both thrombosis and bleeding. 15 Therefore, balancing the prevention of major cardiovascular events while minimising the risk of bleeding is a daily clinical challenge but with the potential of a higher net clinical benefit if antiplatelet and anticoagulant therapies are combined wisely according to the patient's individual risk.
While current ESC STEMI guidelines acknowledge the risk of bleeding in the elderly, a population in whom renal function tends to decrease and the prevalence of comorbidities is high, it is also recommended that there is no upper age limit with respect to reperfusion, especially in patients presenting with STEMI and otherwise candidates for primary percutaneous coronary intervention (PCI). 1 Given the common occurrence of renal dysfunction in this population as well as factors that alter drug metabolism, attention to therapeutic dosing is crucial and creatinine clearance should be routinely estimated for all elderly patients. Dosing adjustment of antithrombotic drugs in elderly patients with ACS is also recommended by the 2015 ESC NSTEACS guidelines. 2 Considerations for dose adjustment according to renal function are summarised in Table 1 . Apart from anticoagulants and the glycoprotein IIb/IIIa inhibitors there is limited evidence for specific dose adjustment for clopidogrel and ticagrelor. Prasugrel is the exception among the P2Y 12 inhibitors in this regard. The maintenance dose should be reduced to 5 mg in patients older than 75 years as well as in patients who weigh less than 60 kg, provided that the drug is in general not recommended as first choice therapy in this population and is contraindicated in patients with a previous history of stroke or a cerebrovascular accident. Cangrelor may be particularly helpful in elderly patients with ACS as it has neither renal nor hepatic metabolism; moreover, it has an ultrashort half-life of a few minutes with a restoration of platelet function within approximately one hour of treatment discontinuation. 16 Radial access rather than a femoral approach should be routinely used whenever possible in patients at high risk of bleeding, including the elderly. 1,2 A transradial approach for PCI in elderly patients (≥70 years) with ACS is also supported by a recent meta-analysis that reports an overall reduced risk for stroke, a lower rate of vascular complications and reduced overall mortality if a transradial approach is used in elderly patients. 17 The recent ESC focused update on dual antiplatelet therapy (DAPT) in patients with CAD may help to address the specific requirements of this treatment in elderly patients with ACS and the need for long-term administration of the drugs. 18 In order to define DAPT duration these guidelines suggest (class IIb, level of evidence A) the use of clinical risk scores that were specifically designed to guide and inform decision in this setting: the PRECISE DAPT score is specifically recommended at the time of coronary stenting, while the DAPT score should be used after one year of uneventful DAPT (Figure 4) . 19, 20 While these scores have not been prospectively validated in randomised controlled trials, the strength of both scores is the inclusion of both ischaemia and bleeding in their calculation and therefore the fact that they consider the net clinical benefit. Importantly, age is included in both scores and is associated with a more pronounced increase in bleeding compared to thrombosis-related events, both in the first year 19 and thereafter. 20 This suggests that, in general, a shorter DAPT duration may be the preferred option in elderly patients.
Anticoagulant drugs in elderly patients with STEMI undergoing primary PCI include unfractionated heparin, enoxaparin and bivalirudin, while the use of fondaparinux is not recommended in this setting. 1, 2 Despite the lack of placebo controlled randomised trials evaluating unfractionated heparin in patients undergoing primary PCI, there is a large body of experience with this agent, which could be considered the first choice. Bivalirudin could also be No specific recommendations for the use of abciximab or for dose adjustment in the case of renal failure. Careful evaluation of haemorrhagic risk is needed CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; iv: intravenous; sc: subcutaneous; aPTT: activated partial thromboplastin time; PCI: percutaneous coronary intervention; GPI: glycoprotein IIB/IIIA inhibitors.
considered in patients at high risk of bleeding (class IIa, level of evidence A) in this setting but there is no clear advantage in elderly patients (Table 1) . 21 On the other hand, in patients with NSTEACS fondaparinux (2.5 mg subcutaneously daily) is recommended as having the most favourable efficacy-safety profile regardless of the management strategy selected in the acute phase. 2 It is still controversial whether antiplatelet therapies recommended in ACS by the current guidelines have a similar safety and efficacy profile in elderly patients compared to a younger population. Several randomised clinical trials are currently addressing this issue. Among them there is the Elderly-ACS 2 Study, which planned to randomise 2000 patients with ACS aged 75 years and older to either prasugrel (60 mg loading dose) 5 mg per day or clopidogrel (300 mg loading dose) 75 mg per day for one year, with the assessment of a combined ischaemic and bleeding endpoint at 12 months. 22 Patient enrolment was interrupted in 2017 after a total of 1455 patients was included, due to futility for efficacy, and the results have been presented at the ESC scientific session in Barcelona. Another randomised study, the POPular AGE Trial, is currently testing the best antiplatelet treatment in NSTEACS patients older than 70 years, comparing prasugrel or ticagrelor (60 mg or 180 mg loading dose, respectively, but no dose reduction other than that recommended by label) with clopidogrel (600 mg loading dose), and evaluating a combined ischaemic and bleeding primary endpoint at 12 months. 23 In summary, antithrombotic therapy in elderly patients with ACS should be managed according to current guidelines, with careful evaluation of bleeding risks and comorbidities that may require dose adjustment, particularly impaired renal function. A radial approach for coronary interventions should be preferred over femoral access. In general, a shorter duration of DAPT may be considered in elderly as compared to younger individuals.
Appropriate level of care
The growing population of elderly patients in the intensive coronary care unit (ICCU) is very heterogeneous and this challenges acute overall management and clinical decisionmaking. Comorbidities are highly prevalent. This prevalence increases exponentially from the age of 60 years, with chronic conditions that tend to cluster. The association of five or more conditions reaches 30% at age 70 years and this is particularly true for cardiovascular comorbidities. 24 Aging may be considered itself as a comorbid situation. Age is associated with an overall decrease in the maximal actual or potential performance frequently due to sarcopenia, an age-related loss of muscle mass and infiltration by fat and connective tissue. Indeed, a decrease in physiological performance with age is true for all our physiological functions, a decline that ultimately leads to a state of exhaustion of functional reserve and increased vulnerability to stressors. This state is called frailty. 25 Frailty is very common in the ICCU population but its prevalence varies widely. 26 It is approximately 50% in patients with acute myocardial infarction 27 aged 75 years and above, 45% in acute heart failure aged over 65 years 28 and more than 80% in patients older than 80 years hospitalised with atrial fibrillation. 29 The prevalence of frailty is probably so high in ICCU patients because frailty and cardiovascular diseases share common biological factors. 25 Cardiovascular conditions contribute directly or indirectly (through lifestyle changes) to subclinical impairments in organ systems and decreased physiological reserve. Moreover, in the ICCU, bed rest and malnutrition contribute to a further rapid decline in muscle mass.
Frailty is a continuous variable that is strongly and independently associated with acute and late mortality, inhospital complications (especially bleeding and delirium), rehospitalisation, long length of stay and poor quality of life. Scales are needed to identify reliably and quantify the severity of frailty. Physicians are relatively good at distinguishing those who are very frail from those who are very fit, but for the large in-between, so common in ICCUs, performance is poor. 25 Standardisation is thus required with two main approaches suggested. The first rests on the phenotypic definition of frailty that bases identification and grading of frail patients on specific signs mainly related to sarcopenia, such as unintentional weight loss, poor grip strength, slow gait speed and low physical activity. The presence of three or more of these signs defines frailty. The second approach defines frailty by the quantity of health impairments in an individual including the consequences of comorbidities. 30 Based on these two paradigms, specific scales have been validated for screening in the acute setting, including the clinical frailty scale ( Figure 5 ) that is easy to use in an intensive care unit (ICU) and correlates with survival and avoidance of institutionalisation. Frailty scores can be used to bridge chronological age to physiological age. 31 A 78-year-old woman with a frailty index that is the one expected for a 93-year-old subject has the life expectancy but also the physiological reserve of a 93-year-old. The reverse is true if her frailty index is one of a 65-year-old individual.
Tailoring acute cardiovascular care for the elderly implies an accurate initial assessment. 32 After securing relief of symptoms and stabilisation of the acute condition, the next step is to estimate life expectancy and dependencyfree survival, and to discuss with the patient and at least his/ her family in order to select together outcomes of highest priority. Most of the time, selected outcomes will be related to quality of life and maintenance of independence over survival. Considering treatment, it is more relevant to go for absolute risk reduction (e.g. number needed to treat). Beyond absolute benefit, the time horizon of benefits (often delayed) and risks (often to be taken early) will have to be balanced. However, there are some hurdles. In the acute setting, asking elderly patients their opinion may not be routinely performed. In one study, in patients over 80 years old admitted to an ICU, only 13% were asked their opinion before referral decision. 33 Interestingly, more than 50% could provide a sound opinion. There were marked variations between centres and physicians. Younger attending physicians were more likely to ask for the patient's opinion, indicating an effect of medical education on physician behaviour in this respect. Family members should be asked about their elderly kin's opinion around priority outcomes, but any reply should then be interpreted with caution. When responses of patients were contrasted with their proxies' answers, there was a high level of discordance, from 24% for tube feeding up to 50% for cardiopulmonary resuscitation. 34 The more debilitating the intervention, the more likely the elderly person was to refuse it while the family would have accepted. A striking contrast was on cardiopulmonary resuscitation. Elderly patients would have expected a try, while family members would have asked for a 'do not resuscitate' order.
Conclusions
Age should not be considered in isolation for clinical decision-making in elderly patients but rather integrated in a comprehensive patient-centred assessment that considers patient preference and expected quality of life in addition to estimated life expectancy. Antithrombotic management should be individualised in elderly patients considering a shorter DAPT duration in patients at high risk of bleeding as well as use of less potent P2Y 12 inhibit (clopidogrel or prasugrel 5 mg per day) and judicious use of drugs with renal metabolism, including inhibitors of the glycoprotein IIb/IIIa receptor. Advanced age should not preclude immediate angiography and reperfusion in STEMI patients. In elderly patients with NSTEACS a routine invasive management by means of radial access should be generally considered in patients younger than 90 years old, especially in the case of normal renal function and good functional status. Skillful clinical assessment remains essential in every patient with suspected ACS and is particularly important in elderly patients who present with specific diagnostic challenges that need to be systematically considered.
